The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis
Open accessAbstract
Summary: Nucleotide-binding, oligomerization domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) gene polymorphism was reported to be associated with susceptibility, disease activity or anti-tumour necrosis factor (TNF) treatment response in rheumatoid arthritis (RA). However, the roles of NLRP3 inflammasome in the development of RA have not yet been elucidated fully. The present study aimed to study the role of NLRP3 inflammasome in RA. NLRP3 inflammasome activation in synovial tissues from RA and osteoarthritis (OA) patients were assessed by Western blot. Active caspase-1 in synovia was stained by a FAM-FLICA caspase-1 probe. Mice with collagen-induced arthritis (CIA) were treated with MCC950, a selective NLRP3 inhibitor, or vehicle for 2 weeks. The clinical score of arthritis, synovial inflammation and cartilage erosion were assessed. Proinflammatory cytokines were measured by enzyme-linked immunosorbent assay (ELISA). The results showed that NLRP3 inflammasome was highly activated in both synovia from RA patients and CIA mice. Activation of NLRP3 inflammasome occurred mainly in the infiltrating monocyte/macrophages in synovia, but not in fibroblast-like synoviocytes. Treatment with MCC950 resulted in significantly less severe joints inflammation and bone destruction. NLRP3 inflammasome activation in the synovia was inhibited significantly by MCC950 with reduced production of interleukin (IL)-1β. The inhibition of NLRP3 inflammasome activation by MCC950 was confirmed further in a human monocytic cell line, THP-1. In conclusion, NLRP3 inflammasome is involved in the pathogenesis of RA. Targeting NLRP3 inflammasome with a small molecule inhibitor might be a novel therapeutic strategy for RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30173-8 · Cited by 4,870
Cytokines in the pathogenesis of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2094 · Cited by 2,529
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
Bartok, B., & Firestein, G. S. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00859.x · Cited by 1,906
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Evidence that cytokines play a role in rheumatoid arthritis
Brennan, F. M., & McInnes, I. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36389 · Cited by 1,103
Regulation of inflammasome activation
Man, S. M., & Kanneganti, T. (2015) · Immunological Reviews · doi:10.1111/imr.12296 · Cited by 1,064
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
Camps, M., Rückle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Françon, B., et al. (2005) · Nature Medicine · doi:10.1038/nm1284 · Cited by 750
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells
Arbore, G., West, E. E., Spolski, R., Robertson, A. A. B., Klos, A., Rheinheimer, C., Dutow, P., Woodruff, T. M., Yu, Z. X., O’Neill, L. A., et al. (2016) · Science · doi:10.1126/science.aad1210 · Cited by 513
Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis
Vande Walle, L., Van Opdenbosch, N., Jacques, P., Fossoul, A., Verheugen, E., Vogel, P., Beyaert, R., Elewaut, D., Kanneganti, T.-D., van Loo, G., et al. (2014) · Nature · doi:10.1038/nature13322 · Cited by 506
Mechanisms of NOD-like Receptor-Associated Inflammasome Activation
Wen, H., Miao, E. A., & Ting, J. P.-Y. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.037 · Cited by 415
The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
Bruchard, M., Rebé, C., Derangère, V., Togbé, D., Ryffel, B., Boidot, R., Humblin, E., Hamman, A., Chalmin, F., Berger, H., et al. (2015) · Nature Immunology · doi:10.1038/ni.3202 · Cited by 395
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Dennis, G., Holweg, C. T., Kummerfeld, S. K., Choy, D. F., Setiadi, A. F., Hackney, J. A., Haverty, P. M., Gilbert, H., Lin, W. Y., Diehl, L., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4555 · Cited by 380
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Cohen, S. B., Moreland, L. W., Cush, J. J., Greenwald, M. W., Block, S., Shergy, W. J., Hanrahan, P. S., Kraishi, M. M., Patel, A., Sun, G., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.016014 · Cited by 305
Terkeltaub, R., Sundy, J. S., Schumacher, H. R., Murphy, F., Bookbinder, S., Biedermann, S., Wu, R., Mellis, S., & Radin, A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.108936 · Cited by 300
Plater-Zyberk, C., Joosten, L. A. B., Helsen, M. M. A., Sattonnet-Roche, P., Siegfried, C., Alouani, S., van de Loo, F. A. J., Graber, P., Aloni, S., Cirillo, R., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12097 · Cited by 240
The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases
de Torre-Minguela, C., Mesa del Castillo, P., & Pelegrín, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00043 · Cited by 238
The role of interleukin‐1 and the inflammasome in gout: Implications for therapy
Pope, R. M., & Tschopp, J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22938 · Cited by 207
Reduced Incidence and Severity of Collagen-Induced Arthritis in Mice Lacking IL-18
Wei, X.-Q., Leung, B. P., Arthur, H. M. L., McInnes, I. B., & Liew, F. Y. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.517 · Cited by 207
The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis
Dayer, J.-M. (2003) · Rheumatology · doi:10.1093/rheumatology/keg326 · Cited by 207
Mathews, R. J., Robinson, J. I., Battellino, M., Wong, C., Taylor, J. C., Eyre, S., Churchman, S. M., Wilson, A. G., Isaacs, J. D., Hyrich, K., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203276 · Cited by 201
Collagen antibody-induced arthritis
Khachigian, L. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.393 · Cited by 195
Choulaki, C., Papadaki, G., Repa, A., Kampouraki, E., Kambas, K., Ritis, K., Bertsias, G., Boumpas, D. T., & Sidiropoulos, P. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0775-2 · Cited by 183
Anakinra for rheumatoid arthritis
Mertens, M., & Singh, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005121.pub3 · Cited by 179
Zhang, H., Wang, S., Huang, Y., Wang, H., Zhao, J., Gaskin, F., Yang, N., & Fu, S. M. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.02.001 · Cited by 129
Self-citationExpression and function of the NALP3 inflammasome in rheumatoid synovium
Kolly, L., Busso, N., Palmer, G., Talabot‐Ayer, D., Chobaz, V., & So, A. K.-L. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03174.x · Cited by 112
Li, X., Shen, W.-W., Sun, Y.-Y., Li, W., Sun, Z., Liu, Y., Zhang, L., Huang, C. Z., Meng, X., & Li, J. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.10.007 · Cited by 99
Self-citationStrand, V., Mease, P. J., Burmester, G. R., Nikaï, E., Coteur, G., van Vollenhoven, R., Combe, B. G., Keystone, E. C., & Kavanaugh, A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2859 · Cited by 93
Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium
Rosengren, S., Hoffman, H. M., Bugbee, W., & Boyle, D. L. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.025577 · Cited by 87
NLRP3 Inflammasome Plays an Important Role in the Pathogenesis of Collagen-Induced Arthritis
Zhang, Y., Zheng, Y., & Li, H. (2016) · Mediators of Inflammation · doi:10.1155/2016/9656270 · Cited by 78
Sode, J., Vogel, U. B., Bank, S., Andersen, P. S., Thomsen, M. K., Hetland, M. L., Locht, H., Heegaard, N. H. H., & Andersen, V. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100361 · Cited by 67
NLRP3 and CARD8 Polymorphisms Influence Higher Disease Activity in Rheumatoid Arthritis
Jenko, B., Praprotnik, S., Tomšič, M., et al. (2016) · Journal of Medical Biochemistry · doi:10.1515/jomb-2016-0008 · Cited by 59
Anakinra for rheumatoid arthritis
Mertens, M. T., & Singh, J. A. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005121.pub2 · Cited by 47
Targeting inflammasomes in rheumatic diseases
So, A. K.-L., Ives, A., Joosten, L. A. B., & Busso, N. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.61 · Cited by 31
Wang, H., Zhao, J., Zhang, H., Huang, Y., Wang, S., Tu, Q., & Yang, N. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12275 · Cited by 16
Self-citation
Cited by
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
The NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Li, H., Guan, Y., Liang, B., Ding, P., Hou, X., Wei, W., & Ma, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175091 · Cited by 258
Metadata
- Authors
- Guo, C., Fu, R., Wang, S., Huang, Y., Li, X., Zhou, M., Zhao, J., & Yang, N.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-09-16
- Volume
- 194
- Issue
- 2
- Pages
- 231-243
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2891100999
- Cited by
- 285
- References
- 42
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.